Home > Boards > US OTC > Medical - Drugs >

NeuroVive Pharmaceutical AB (NEVPF)

NEVPF RSS Feed
Add NEVPF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 6/4/2019 12:17:36 PM - Followers: 0 - Board type: Free - Posts Today: 0

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for genetic mitochondrial diseases and one project in preparation for a clinical phase II efficacy study for the prevention of moderate to severe traumatic brain injury (NeuroSTAT). The R&D portfolio also consists of projects for genetic mitochondrial disorders, NASH and cancer. The company advances drugs for rare diseases through clinical development into the market with our without partners. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive's NVP015 program was in 2018 licenced to Fortify Therapeutics, a BridgeBio company, for local treatment of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
NEVPF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#7   Such little volume here we won't be able Chrisny73 06/04/19 12:17:36 PM
#6   cents to a dollar here..... Chrisny73 05/17/19 01:04:51 PM
#5   Looking for an entry point at .10 Chrisny73 05/17/19 01:03:05 PM
#4   Orphan drug huge Chrisny73 05/17/19 01:01:29 PM
#3   Lotsa potential here Chrisny73 05/17/19 12:59:37 PM
#2   Looking for a possible entry point at like Chrisny73 05/14/19 12:15:35 PM
#1   Looks like this stock has potential.... orphan drug Chrisny73 05/14/19 12:13:58 PM
PostSubject